Related Experiment Video
Updated: Jan 18, 2026

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
Published on: March 31, 2019
YTHDC1 orchestrates oncogenic splicing via the CLK1-SRSF1 splicing machinery to regulate castration-resistant
Parth Gupta1, Devesh Srivastava1, Vinayak Nayak1
1Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, 502285, India.
Abstract:
Androgen receptor variant 7 (AR-V7) plays a critical role in castration-resistant prostate cancer (CRPC) progression even under androgen-deprivation conditions. Clinical and experimental studies have established that AR-V7 expression is a critical driver of CRPC progression and resistance to first-line anti-androgen therapy including enzalutamide. Understanding the mechanisms regulating AR-V7 generation and its contribution to drug resistance is critical for developing newer approaches to target CRPC. In this study, we have investigated the role of the RNA-binding protein YTHDC1, a m6A reader, in regulating AR-V7 splicing. Our findings reveal that YTHDC1 is overexpressed in CRPC and modulating its expression directly affects AR-V7 levels, rendering the cells sensitive to enzalutamide treatment. Mechanistically, we demonstrate that YTHDC1 binds to the AR-V7 pre-mRNA and facilitates the recruitment of phosphorylated SRSF1, a splice factor that promotes AR-V7 splicing. Additionally, we also demonstrate that it modulates the levels of CLK1, a known SRSF1 kinase supporting its role in regulating AR-V7 splicing. Furthermore, our experiments also reveal that YTHDC1 regulates the expression of other oncogenic transcripts, including Bcl-2, Cyclin D1, Nova1, and VEGF-A, highlighting its broader role in cancer progression. Overall, our study supports that targeting YTHDC1 could be a novel therapeutic approach to overcome AR-V7-mediated treatment resistance in CRPC patients.
Insights
Androgen receptor variant 7 (AR-V7) drives prostate cancer progression and enzalutamide resistance. Targeting YTHDC1 RNA-binding protein can restore enzalutamide sensitivity by reducing AR-V7 levels.
Area of Science:
- Molecular Oncology
- RNA Biology
- Cancer Therapeutics
Background:
- Androgen receptor variant 7 (AR-V7) is a key driver of castration-resistant prostate cancer (CRPC) progression.
- AR-V7 expression confers resistance to anti-androgen therapies like enzalutamide.
- Understanding AR-V7 regulation is crucial for developing novel CRPC treatments.
Purpose of the Study:
- To investigate the role of RNA-binding protein YTHDC1 in regulating AR-V7 splicing.
- To explore YTHDC1 as a potential therapeutic target for overcoming enzalutamide resistance in CRPC.
Main Methods:
- Investigated YTHDC1 expression in CRPC samples.
- Assessed the impact of modulating YTHDC1 expression on AR-V7 levels and enzalutamide sensitivity.
- Elucidated the mechanism of YTHDC1-mediated AR-V7 splicing involving SRSF1 and CLK1.
- Examined YTHDC1's regulation of other oncogenic transcripts.
Main Results:
- YTHDC1 is overexpressed in CRPC and its modulation affects AR-V7 levels.
- Targeting YTHDC1 restores enzalutamide sensitivity in CRPC cells.
- YTHDC1 facilitates AR-V7 splicing by recruiting phosphorylated SRSF1 and modulating CLK1.
- YTHDC1 also regulates other oncogenic transcripts like Bcl-2, Cyclin D1, Nova1, and VEGF-A.
Conclusions:
- YTHDC1 plays a significant role in AR-V7 generation and CRPC progression.
- Targeting YTHDC1 presents a novel therapeutic strategy to overcome AR-V7-mediated enzalutamide resistance in CRPC patients.
Related Concept Videos
Anaphase Promoting Complex
RNA Splicing
Abnormal Proliferation
Hedgehog Signaling Pathway
Inhibition of Cdk Activity
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...

